Document ID: chunk:federal_register_of_legislation:F2025C00158:reg:24
Version: federal_register_of_legislation:F2025C00158
Segment Type: reg
Provision Reference: reg 24
Character Range: 29164–30401

24  Transitional provision—authorisation of prescriptions
 (1) This section applies in relation to prescriptions for the supply of pharmaceutical benefits written before 1 July 2024.
 (2) Despite the repeal of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012:
 (a) an authorised prescriber may submit a prescription to the Chief Executive Medicare in accordance with section 12 of that instrument as in force immediately before 1 April 2024; and
 (b) the Chief Executive Medicare may authorise the prescription in accordance with section 13 of that instrument as in force immediately before 1 April 2024; and
 (c) if the prescription is so authorised, writing the prescription is taken to have been authorised in accordance with section 19 of this instrument.
 (3) If the Chief Executive Medicare authorises a prescription under subsection 13(1), (1A) or (1B) of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 as in force immediately before 1 April 2024, the authorised prescriber is not required to comply with the following provisions of the National Health (Pharmaceutical Benefits) Regulations 2017 in relation to the prescription:
 (a) paragraph 40(1)(i);
 (b) paragraph 41(3)(a).